Inozyme Pharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
SCHEDULE: Beryl Capital Exits Inozyme Pharma Stake
Beryl Capital Management and related entities report 0% beneficial ownership in Inozyme Pharma, Inc., signaling a complete divestment.
Rock Springs Capital and its affiliates have reported a complete divestment of their beneficial ownership in Inozyme Pharma, Inc., now holding 0% of common stock.
Adage Capital Management and its principals have filed an amendment indicating their beneficial ownership in Inozyme Pharma, Inc. will be 0% as of June 30, 2025, signaling a complete planned divestment.
SCHEDULE 13G: Glazer Capital Discloses 6.59% Stake in Inozyme Pharma
Glazer Capital, LLC and its managing member Paul J. Glazer have disclosed a beneficial ownership of 6.59% of Inozyme Pharma, Inc.'s common stock, totaling 4,251,940 shares.
Affinity Healthcare Fund, LP and its investment manager, Affinity Asset Advisors, LLC, have filed an amended Schedule 13G disclosing a passive beneficial ownership of 2.89% in Inozyme Pharma, Inc.
Beryl Capital Management and its affiliates have disclosed a passive beneficial ownership of 9.8% of Inozyme Pharma, Inc.'s common stock, totaling 6,321,584 shares.
SCHEDULE 13G/A: Eventide Asset Management and Affiliates Report Reduced Stake in Inozyme Pharma Below 5%
Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, have reported a beneficial ownership of 3.46% in Inozyme Pharma, Inc., indicating a position below the 5% threshold for passive investors.
SCHEDULE 13G/A: Samlyn Capital, LP, and Robert Pohly Report Zero Beneficial Ownership in Inozyme Pharma, Inc.
Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Inozyme Pharma, Inc. as of December 31, 2024.